The GnRH agonist was more efficient than the aromatase inhibitor in controlling chronic pelvic pain (CPP) (p = 0.04), but they were equally efficient in managing dysmenorrhea and dyspareunia. The gene discussed is GNRH1; the disease is Dyspareunia.